BioNTech Deal Shows Pfizer Is Reinvesting COVID-19 Windfall In mRNA
The companies’ third vaccine-development deal shows how COVID cash has also led mRNA-focused companies to beef up their organic pipelines amid talk of a merger wave.
You may also be interested in...
Spikevax revenues beat expectations but analysts are bracing for the eventuality of lower vaccine revenues as COVID-19 becomes endemic. Moderna will have four new vaccines in Phase III this quarter.
The potential for RNA medicines to achieve holy grail goals – reaching undruggable targets and bringing drugs to market faster – has Pfizer, Lilly, Novartis and others in a deal-making frame of mind.
Zydus Cadila sees 40-50% growth continuing in its biosimilars business, with plans for launches in Latin America. Its Kadcyla biosimilar is faring well and after helping the company gain the top spot in India, could also move to clinical trials in the US.